Skip to content
Screener

LENSAR, Inc. LNSR EPS (Diluted)

EPS (Diluted) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.27-0.9%
Staar Surgical logo
Staar SurgicalSTAA
$0.16+147%
Bausch + Lomb logo
Bausch + LombBLCO
-$0.04+77.8%
RxSight, Inc. logo
RxSight, Inc.RXST
-$0.290.0%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$0.32-45.5%
Schering-Plough logo
Schering-PloughSGP
-$0.69+82.6%

Other financials

Income statement

See full
Revenue$16.5M+18.4%
Gross profit$9.8M+39.2%
Operating income$2.1M+134%
Net income$3.5M+300%

Balance sheet

See full
Cash & equivalents$13.6M+89.7%
Total debt$6.1M+163%
Total equity$14.9M+165%
Total assets$69.6M-1.2%

Cash flow

See full
Operating cash flow-$127.0K+97.5%
CapEx$77.0K-31.9%
Free cash flow-

Valuation

See full
Market cap$93.86M-36.3%
Enterprise value$86.43M-39.4%
P/E2.7×
P/S1.6×-1.0×

Profitability

See full
Gross margin48.3%+1.2pp
Operating margin-13.5%-4.3pp
Net margin57.6%+36.1pp
FCF margin-26.6%

Returns & leverage

See full
Return on equity-164%-235pp
Debt / equity0.4×
Current ratio2.4×+0.9×

Where this comes from

Reported directly by LENSAR, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: LENSAR, Inc.’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-349315
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Change in unrealized loss on investments(6)(4)(9)
Net income (loss) and comprehensive income (loss)$3,535$(1,770)$39,863$(29,118)
Income (loss) per common share:
Basic$0.14$(0.15)$1.62$(2.46)
Diluted$0.10$(0.15)$0.61$(2.46)
Weighted-average number of common shares used in calculation of net income (loss) per common share:
Basic12,29711,93712,23011,856
Diluted23,02711,93724,02411,856

Item 1. Financial Statements.

FAQ

What is LENSAR, Inc.'s EPS (diluted)?
LENSAR, Inc. (LNSR) reported EPS (diluted) of $0.10 in Q2 2026.
How has LENSAR, Inc.'s EPS (diluted) changed year-over-year?
LENSAR, Inc.'s EPS (diluted) increased by 166.7% year-over-year, from -$0.15 to $0.10.
What is the long-term trend for LENSAR, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), LENSAR, Inc.'s EPS (diluted) has grown at a 8.7% compound annual growth rate (CAGR), from -$2.08 to -$2.90.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about LENSAR, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude